Navigation Links
BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
Date:12/10/2013

JERUSALEM, Dec. 10, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive preclinical results of BL-8040 (formerly known as BKT-140), for the treatment of Acute Myeloid Leukemia (AML) and other hematological indications, have been presented as a poster at the 55th Annual Meeting of the American Society of Hematology (ASH). The data show that BL-8040 is efficient in inducing the death of AML cancer cells both in vitro and in a humanized mouse model.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

BL-8040 is a novel, potent and selective inhibitor of the CXCR4 chemokine receptor, which is normally activated by the chemokine ligand CXCL12. Both CXCL12 and its receptor, CXCR4, are key players in enabling AML cancer cells to hide and thrive in the bone marrow, and CXCR4 expression in AML patients is associated with poor prognosis. FLT3 mutations are detected in approximately 30% of AML cases and are associated with poor prognosis and a high incidence of relapse in AML patients. In addition, expression of the CXCR4 receptor in FLT3 mutated AML is also correlated with poor outcomes. Accordingly, it is believed that inhibition of CXCR4 may sensitize AML cells toward chemotherapy and FLT-3 targeted therapies.

The data presented in the conference show that BL-8040 directly inhibits AML cell growth and induces cell death, both in cell cultures and in mice engrafted with human AML cells. In addition, the ability of BL-8040 to induce mobilization of AML cells from the bone marrow into the blood circulation enhanced the chemotherapeutic effect of ARA-C (one of the standard-of-care chemotherapies for AML). The effects were even more robust in cells harboring the FLT3 mutation and a synergistic
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
2. BioLineRx Reports Second Quarter 2013 Results
3. BioLineRx Appoints B. J. Bormann to Board of Directors
4. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
5. BioLineRx to Present at 15th International Celiac Disease Symposium
6. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
11. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 According to a ... "Latin America Home Healthcare Market (By Device Types: ... Mobility Assist Devices and Medical Supplies; By Services: ... and Unskilled Home Healthcare Services) - Industry Analysis, ... 2020" the Latin American Home Healthcare market was ...
(Date:9/2/2014)... 2014 According to the new ... Analytical, Preparative), by Material (Metal, Glass, Plastic), by Application ... to 2018", published by MarketsandMarkets, the Chiral Chromatography Columns ... poised to grow at a CAGR of 5.2% from ... Browse 90 market data tables and 15 figures ...
(Date:9/2/2014)... , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... present an overview of the company at the Morgan Stanley ... , Presentation date: Tuesday September 9, 2014 ... A live webcast and 30-day archive of this presentation will ... Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a ...
Breaking Medicine Technology:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... 15 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), ... present a company overview at the 17th Annual NewsMakers in ... 11:00 a.m. ET at the Millennium Broadway Hotel & Conference ... of the presentation will be available on the "Investors & ...
... Md., Oct. 15 /PRNewswire-Asia/ -- Synutra International, Inc. (Nasdaq: ... in China and a producer, marketer and seller of ... that the Company will present at Citi,s Greater China ... the Grand Hyatt Macau.  Management is currently scheduled to ...
Cached Medicine Technology:
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, 2014 (HealthDay ... behind the rising rates of type 2 diabetes, according to ... national surveys spanning from 1976 through 2010 to determine how ... by factors such as changing distribution of race, age and ... prevalence of diabetes in men rose from about 5 percent ...
(Date:9/2/2014)... (HealthDay News) -- Melatonin supplements did not reduce delirium ... new study found. Many older hospital patients experience ... disruption of their normal sleep-wake cycle. A lack of ... to delirium, but there has been little research into ... study included 378 patients, average age 84, who had ...
(Date:9/2/2014)... and marijuana may lead to different types of harmful ... analyzed 2007 to 2011 data gathered from more than ... used alcohol or marijuana at least once. The ... unsafe driving, damage to relationships with friends and romantic ... of alcohol, especially among females. On the ...
(Date:9/2/2014)... in locations with less intensive (and expensive) practice patterns ... that spare patients unnecessary and excessive medical care, according ... . , "Growing concern about the costs and harms ... ability to avoid the provision of unnecessary care," said ... and The Dartmouth Institute for Health Policy & ...
Breaking Medicine News(10 mins):Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:Residency training predicts physicians' ability to practice conservatively 2
... WASHINGTON, Sept. 18 Americans believe that,providing medical care ... top of our nation,s priorities, in line with resolving ... a new nationwide survey. What,s,more, three-quarters of the public ... military veterans., And what do Americans think should ...
... identified specific damages to the brain that may occur when ... study in mice found that those animals that lived alone ... more damage to neurons in one part of the brain ... studies in humans have shown that socially isolated heart attack ...
... primarily for blind people places a layer of information technology ... interest along their path as they pass them. , The ... of Michigan. Researchers will present their work at two conferences ... A to point B. They learn to count steps if ...
... is almost always adenocarcinoma or signet ring cell carcinoma ... cell carcinoma. We report a patient with adenocarcinoma of ... This is the first reported case of gastric cancer ... to be published on 28 May 2008 in the ...
... numerous randomized clinical trials (RCT) have evaluated, and ... treatment regimens. Surgery remains standard care for early ... have also shown a survival benefit associated with ... patterns of care for these cancers. A study ...
... Introduced, MINNEAPOLIS, Sept. 17 Today ClearWay ... Board Members and,thanked outgoing members for their service ... and Executive Director of the Honeywell,Foundation as well ... affairs for Honeywell, was elected as the new ...
Cached Medicine News:Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 2Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 3Health News:Study suggests why heart attack victims do better with social support 2Health News:Study suggests why heart attack victims do better with social support 3Health News:New Bluetooth system orients blind and sighted pedestrians 2Health News:New Bluetooth system orients blind and sighted pedestrians 3Health News:How to treat gastroesophageal adenocarcinom patients? 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: